Agios Pharma (AGIO) Misses Q4 EPS by 10c

Agios Pharma (NASDAQ: AGIO) reported Q4 EPS of ($1.72), $0.10 worse than the analyst estimate of ($1.62). Revenue for the quarter came in at $7.1 million versus the consensus estimate of $7.94 million.

For earnings history and earnings-related data on Agios Pharma (AGIO) click here.

You May Also Be Interested In

• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
• Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance
• Piper Sandler on Fervo Energy (FRVO): 'Capital Access Supports Potential Upside'